Comparison Overview

Lincoln Pharmaceuticals Ltd

VS

MSD

Lincoln Pharmaceuticals Ltd

Science City Road, Ahmedabad, Gujarat, 380060, IN
Last Update: 2025-05-06 (UTC)

Lincoln is proud of its manufacturing capabilities. We are really distinct and powerful when it comes to the production capacity. Set up in the year 1979, the manufacturing facility of Lincoln is based at Khatraj, Gujarat sharing the same dais as with the international standards. Another manufacturing setup at Mehsana, Gujarat and Head Office in Ahemedabad city of Gujarat. There are global standards and norms which a manufacturing lab should scan through and we ensure that our processes are in compliance with WHO-cGMP norms. Our lab has been given ISO 9001:2015 certifications; thoroughly highlighting Lincoln’s dedication in direction of high quality and safety. These certifications and achievement has added new feather to out hat. With these achievements, we also furthermore plan to expand the capabilities in the US and UK markets making the presence global and more rewarding.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 807
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

MSD

90 E Scott Ave, Rahway, New Jersey, 07065, US
Last Update: 2025-03-04 (UTC)
Between 800 and 849

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 39,765
Subsidiaries: 34
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/lincoln-pharmaceuticals-ltd.jpeg
Lincoln Pharmaceuticals Ltd
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/msd-global.jpeg
MSD
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Lincoln Pharmaceuticals Ltd
100%
Compliance Rate
0/4 Standards Verified
MSD
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Lincoln Pharmaceuticals Ltd in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MSD in 2025.

Incident History — Lincoln Pharmaceuticals Ltd (X = Date, Y = Severity)

Lincoln Pharmaceuticals Ltd cyber incidents detection timeline including parent company and subsidiaries

Incident History — MSD (X = Date, Y = Severity)

MSD cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/lincoln-pharmaceuticals-ltd.jpeg
Lincoln Pharmaceuticals Ltd
Incidents

No Incident

https://images.rankiteo.com/companyimages/msd-global.jpeg
MSD
Incidents

No Incident

FAQ

MSD company demonstrates a stronger AI Cybersecurity Score compared to Lincoln Pharmaceuticals Ltd company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, MSD company has disclosed a higher number of cyber incidents compared to Lincoln Pharmaceuticals Ltd company.

In the current year, MSD company and Lincoln Pharmaceuticals Ltd company have not reported any cyber incidents.

Neither MSD company nor Lincoln Pharmaceuticals Ltd company has reported experiencing a ransomware attack publicly.

Neither MSD company nor Lincoln Pharmaceuticals Ltd company has reported experiencing a data breach publicly.

Neither MSD company nor Lincoln Pharmaceuticals Ltd company has reported experiencing targeted cyberattacks publicly.

Neither Lincoln Pharmaceuticals Ltd company nor MSD company has reported experiencing or disclosing vulnerabilities publicly.

Neither Lincoln Pharmaceuticals Ltd nor MSD holds any compliance certifications.

Neither company holds any compliance certifications.

MSD company has more subsidiaries worldwide compared to Lincoln Pharmaceuticals Ltd company.

MSD company employs more people globally than Lincoln Pharmaceuticals Ltd company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Lincoln Pharmaceuticals Ltd nor MSD holds SOC 2 Type 1 certification.

Neither Lincoln Pharmaceuticals Ltd nor MSD holds SOC 2 Type 2 certification.

Neither Lincoln Pharmaceuticals Ltd nor MSD holds ISO 27001 certification.

Neither Lincoln Pharmaceuticals Ltd nor MSD holds PCI DSS certification.

Neither Lincoln Pharmaceuticals Ltd nor MSD holds HIPAA certification.

Neither Lincoln Pharmaceuticals Ltd nor MSD holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X